CMPX
Compass Therapeutics·NASDAQ
--
--(--)
--
--(--)
CMPX fundamentals
Compass Therapeutics (CMPX) released its earnings on Aug 11, 2025: revenue was 0 (YoY -100.00%), met estimates; EPS was -0.14 (YoY -40.00%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.14
-40.00%
Report date
Aug 11, 2025
Earnings Call
8:00 AM on Aug 11, 2025
Meeting link.EPS
Actual | -0.1 | -0.15 | -0.07 | -0.08 | -0.12 | -0.1 | -0.06 | -0.09 | -0.08 | -0.11 | -0.08 | -0.1 | -0.08 | -0.11 | -0.12 | -0.14 |
Forecast | -0.11 | -0.0914 | -0.1029 | -0.0829 | -0.105 | -0.1113 | -0.1063 | -0.0814 | -0.1071 | -0.0943 | -0.1129 | -0.0964 | -0.1129 | -0.0981 | -0.11 | -0.124 |
Surprise | +9.09% | -64.11% | +31.97% | +3.50% | -14.29% | +10.15% | +43.56% | -10.57% | +25.30% | -16.65% | +29.14% | -3.73% | +29.14% | -12.13% | -9.09% | -12.90% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 875.00K | 0 | 0 | 0 | 0 |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What factors drove the changes in Compass Therapeutics's revenue and profit?What does Compass Therapeutics do and what are its main business segments?What is the revenue and EPS growth rate for Compass Therapeutics year over year?What were the key takeaways from Compass Therapeutics's earnings call?What were the key takeaways from Compass Therapeutics’s earnings call?What guidance did Compass Therapeutics's management provide for the next earnings period?What is Compass Therapeutics's latest dividend and current dividend yield?Did Compass Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
